Stran je namenjena samo zdravstvenim delavcem s prebivališčem v Republiki Sloveniji.

Search

Menu

Close

PrijavaOdjava
Naša zdravilaTerapevtska področjaMedia CenterMedia CenterDogodkiGradivaVideo vsebinePovežimo sePovežimo seKontaktirajte nasMedicinske informacije družbe Pfizer

Menu

Close

About Prevenar 20™ at a Glance Serotype Coverage Pneumococcal Disease Clinical Programme RecommendationsPractical Use Resources
Practical use of Prevenar 20™ (Pneumococcal 20-valent Conjugate Vaccine)Prevenar 20™ is administered the same way as Prevenar 13® (Pneumococcal 13-valent Conjugate Vaccine)1,2 Similarities shared by Prevenar* vaccines simplify transition to a higher-valent pneumococcal conjugate vaccine (PCV)1,2

Prevenar 20™ uses the same syringe as Prevenar 13®, with a different colour finger grip.

Prevenar includes Prevenar 13® and Prevenar 20TM. For paediatric use in [Country], Prevenar 13® has been available since 2010 and Prevenar 20TM since 2023.1,2,5
Simple steps for syringe preparation
Prevenar 20™ can be coadministered with the [Local body]-recommended infant immunisation schedule.1,3
Storage and handling for Prevenar 20™
  • With the approval of the paediatric indication(s), the Apexxnar® name has changed to Prevenar 20™
  • [Local body] permits Apexxnar® packaged products to be used for all Prevenar 20™ indicated age groups [with accompanying leaflet]
  • Dosing and administration remain the same for both products

Please refer to the Prevenar 20™ Summary of Product Characteristics for full dosing and administration recommendations.

Stability data indicate that the vaccine is stable for 96 hours when stored at temperatures from 8°C to 25°C, or 72 hours when stored at temperatures from 0°C to 2°C. At the end of these time periods, Prevenar 20™ should be used or discarded. These data are intended to guide healthcare professionals in case of temporary temperature excursion only.1References:Prevenar 20™ (Pneumococcal 20-valent Conjugate Vaccine). Summary of Product Characteristics. Wyeth Pharmaceuticals LLC; 2024.Prevenar 13® (Pneumococcal 13-valent Conjugate Vaccine). Summary of Product Characteristics. Wyeth Pharmaceuticals LLC; 2014.Centers for Disease Control and Prevention. ACIP updates: recommendations for the use of 20-valent pneumococcal conjugate vaccine in children—United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(39):1072. https://stacks.cdc.gov/view/cdc/133252.Vaxneuvance™ (Pneumococcal 15-valent Conjugate Vaccine). Summary of Product Characteristics. Merck Sharp & Dohme Corp.; 2023.Local approval dates. The broadest serotype coverage for babies in a pneumococcal conjugate vaccine1,2,4 Learn more Loading
PP-PNR-GLB-0425 March 2024
PfizerPro računPfizerPro račun

Za dostop do dodatnih gradiv, vsebin in prejemanje sporočil o zdravilih in cepivih družbe Pfizer

VpisRegistracijaRačunOdjava

To spletno mesto je namenjeno samo zdravstvenim delavcem s prebivališčem v Republiki Sloveniji. Če se uvrščate med širšo javnost in bi želeli dostopati do informacij o določenem zdravilu, se, prosimo, obrnite na vašega zdravnika ali farmacevta.

 

To spletno stran vam ponuja Pfizer, podružnica Ljubljana.

 

Avtorske pravice 2022 Pfizer, podružnica Ljubljana. Vse pravice pridržane.


Davčna številka: SI 17966086

PP-UNP-SVN-0142, datum priprave: september 2023
Zapuščate PfizerPro
​
Zapuščate spletno mesto, ki ga upravlja Pfizer. Povezave do vseh zunanjih spletnih mest so na voljo kot vir za naše obiskovalce. Pfizer ne prevzema odgovornosti za vsebino spletnih mest, ki niso v lasti in upravljanju družbe Pfizer.
 
PP-UNP-SVN-0142
datum priprave: september 2023
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​ Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​